| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/03/2002 | WO2002000821A2 A novel polypeptide, a human protein plp39 and the polynucleotide encoding the polypeptide |
| 01/03/2002 | WO2002000778A1 The preparation method of a stable polymer aqueous phase-aqueous phase emulsion and its use |
| 01/03/2002 | WO2002000768A1 Mammalion haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000724A2 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | WO2002000723A2 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | WO2002000717A2 Novel co-stimulatory molecules |
| 01/03/2002 | WO2002000713A1 Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen |
| 01/03/2002 | WO2002000711A2 Ev-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000709A2 Cerebellin homologous polypeptides and therapeutic uses thereof |
| 01/03/2002 | WO2002000704A2 Regulation of human phospholipase c-like enzyme |
| 01/03/2002 | WO2002000702A2 Regulation of human epidermis-specific serine protease |
| 01/03/2002 | WO2002000701A2 Regulation of human gonadotropin releasing hormone receptor-like g protein-coupled receptor |
| 01/03/2002 | WO2002000700A2 Regulation of human p2y8-like g protein-coupled receptor |
| 01/03/2002 | WO2002000695A2 Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000690A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | WO2002000688A1 Peptide compound and pharmaceutical compositions and medicines containing the same as the active ingredient |
| 01/03/2002 | WO2002000687A2 Antimicrobial peptides and methods of use thereof |
| 01/03/2002 | WO2002000684A2 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 01/03/2002 | WO2002000677A1 Nucleic acids, proteins, and antibodies |
| 01/03/2002 | WO2002000641A2 Spla2 inhibitors |
| 01/03/2002 | WO2002000263A2 Tripeptide prodrug compounds |
| 01/03/2002 | WO2002000262A2 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | WO2002000261A2 Surfactant-containing formulations for extended release of somatotropin |
| 01/03/2002 | WO2002000258A1 Medicinal compositions for angiogenic therapy |
| 01/03/2002 | WO2002000254A2 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 01/03/2002 | WO2002000250A2 Hiv-1 vaccines and screening methods therefor |
| 01/03/2002 | WO2002000248A2 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| 01/03/2002 | WO2002000247A1 Reversal of antibiotic resistance with lysozyme dimer |
| 01/03/2002 | WO2002000246A2 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency |
| 01/03/2002 | WO2002000245A1 Neurotoxic oligomers |
| 01/03/2002 | WO2002000244A2 Protein mixtures for wound healing |
| 01/03/2002 | WO2002000243A2 Stabilized interleukin 2 |
| 01/03/2002 | WO2002000242A2 Human papilloma virus treatment |
| 01/03/2002 | WO2002000241A2 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide |
| 01/03/2002 | WO2002000233A2 Purging of cells using viruses |
| 01/03/2002 | WO2002000229A1 Method for the production of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross-linking in the presence of chemically non-reacting effectors of the oxygen affinity of the haemoglobin |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000207A1 The controlled release preparation of insulin and its method |
| 01/03/2002 | WO2002000200A1 Novel process for preparing crystalline particles |
| 01/03/2002 | WO2002000174A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/03/2002 | WO2002000173A2 Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000171A2 Composition for delivery of hematopoietic growth factor |
| 01/03/2002 | WO2002000170A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | WO2002000149A1 Polymeric, fiber matrix delivery systems for bioactive compounds |
| 01/03/2002 | WO2002000137A1 Biodegradable vehicles and delivery systems of biologically active substances |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001075033A3 A novel polypeptide, a human cell division cycle regulatory protein 9 and the polynucleotide encoding the polypeptide |
| 01/03/2002 | WO2001072828A3 26649, a human gtpase activating molecule and uses therefor |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001068126A3 Methods and compositions for treating premature rupture of fetal membranes |
| 01/03/2002 | WO2001066708A3 MATERIALS AND METHODS RELATING TO THE DEGRADATION OF Cdc25A IN RESPONSE TO DNA DAMAGE |
| 01/03/2002 | WO2001066564A3 Gamma-secretase inhibitors |
| 01/03/2002 | WO2001066063A3 Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis |
| 01/03/2002 | WO2001064880A3 Human dynamin 40322 |
| 01/03/2002 | WO2001059117A3 Seven-transmembrane proteins/g-protein coupled receptors |
| 01/03/2002 | WO2001058941A8 Cytokine activity regulator molecules from tick salivary glands |
| 01/03/2002 | WO2001058472A3 Botulinum toxin pharmaceutical compositions |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001055317A3 Nucleic acids, proteins, and antibodies |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001049314A3 Glp-2 formulations |
| 01/03/2002 | WO2001047958A3 Kunitz domain polypeptide zkun10 |
| 01/03/2002 | WO2001046421A3 Zcys5: a member of the cystatin superfamily |
| 01/03/2002 | WO2001046383A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 01/03/2002 | WO2001046219A3 Method for production of a c1 esterase inhibitor (c1-inh)-containing composition |
| 01/03/2002 | WO2001042297A3 Clasp-3 transmembrane protein |
| 01/03/2002 | WO2001041813A3 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 01/03/2002 | WO2001040291A3 Proteins and nucleic acids encoding the same |
| 01/03/2002 | WO2001039799A3 Passive desensitization |
| 01/03/2002 | WO2001037853A9 Methods and agents for the inhibition of smooth muscle cell proliferation |
| 01/03/2002 | WO2001032843A3 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 01/03/2002 | WO2001028532A3 Methods and compositions for predicting, diagnosing and treating lipodystrophy |
| 01/03/2002 | WO2001027334A3 Methods and compositions for correlating ccr5 expression with essential hypertension |
| 01/03/2002 | WO2001023553A8 Metastasis-associated antigen c4.4a |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | WO2000059935A9 Anti-apoptotic fusion polypeptide |
| 01/03/2002 | US20020002353 Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device |
| 01/03/2002 | US20020002283 Process for preparing growth hormone secretagogues |
| 01/03/2002 | US20020002277 Inhibitors of platelet activation and recruitment |
| 01/03/2002 | US20020002276 Chimeric heteromultimer adhesins |
| 01/03/2002 | US20020002271 Separating immunoglobulin from mixture; load sample onto chromatographic apparatus, elute immunoglobulin |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002163 1,4-benzodiazepinones and their uses as CCK antagonists |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020002136 Salts of glutathione |
| 01/03/2002 | US20020002135 Pharmaceutical use |
| 01/03/2002 | US20020002134 PAI-2 conjugates for the treatment and imaging of cancer |
| 01/03/2002 | US20020002133 Stabilized granulocyte colony stimulating factor |
| 01/03/2002 | US20020002132 Use of interleukin-4 antagonists and compositions thereof |
| 01/03/2002 | US20020002131 Providing exogenous antiangiogenic protein to endothelial cells associated with said tissue |
| 01/03/2002 | US20020001840 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 01/03/2002 | US20020001828 Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities |
| 01/03/2002 | US20020001825 Fibroblast growth factor-like molecules and uses thereof |